Europe
Rise in populism linked to vaccine hesitancy in Europe, study shows
February 26, 2019Manufacturing and Production EU, Europe, populism, populist parties, vaccine hesitancy, vaccines
Parent’s reluctance to vaccinate their children correlates with the number of people voting for populist parties, according to a study …
Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma
February 14, 2019Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma
Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …
BMS scores expanded European approval for Sprycel in paediatric leukaemia
February 13, 2019Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma
Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …
Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent
February 4, 2019Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent
It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee …
Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia
January 23, 2019Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma
The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …
Seqirus secures first cell-based quadrivalent influenza vaccine approval in Europe
January 14, 2019Sales and Marketing Europe, Flucelvax, flu, influenza, pharma, seqirus
Seqirus has made it known that its new cell-based seasonal influenza vaccine Flucelvax Tetra has been approved by the European …
EMA approves more new active substances in 2018, but total recommendations fall
January 14, 2019Sales and Marketing EMA, EU, Europe, drug approvals, pahrma
2018 was a strong year for European approvals according to the EMA; the regulator has recently released its Human medicines …
Shire’s Takhzyro scores EU approval in rare genetic disorder hereditary angioedema
December 3, 2018Sales and Marketing EU, Europe, Shire, Takhzyro, pharma
Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of …
MSD chalks up two HIV drug approvals in Europe
November 30, 2018Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …
Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS
November 29, 2018Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …
European Commission approves first and only long-acting opioid dependence therapy
November 26, 2018Sales and Marketing Europe, opioid crisis, opioids, pharma
Europe has seen its first and only approval of a long-acting therapy for opioid dependence, as the European Commission (EC) …
Mundipharma’s Neulasta biosimilar approved in EU
November 26, 2018Sales and Marketing Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma
Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European …
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
First-ever all-oral drug for sleeping sickness recommended for approval by EMA committee
November 20, 2018Manufacturing and Production, Sales and Marketing CHMP, EMA, Europe, Sanofi, fexinidazole, pharma, sleeping sickness
Sanofi’s fexinidazole, the first all-oral therapy for the treatment of human African trypanosomiasis (HAT), or sleeping sickness, has secured a …
Eli Lilly’s Emgality cleared for treatment of migraine in Europe
November 20, 2018Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma
Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
